Small Molecules

Amiodarone

Quality Solutions

Category: Cardiovascular



Authorized Distributor

USP can support your development and manufacturing activities on Amiodarone-based medicines with these existing and upcoming standards.

Official and Proposed Documentary Standards and Associated Physical Materials

MONOGRAPH 1

AMIODARONE HYDROCHLORIDE Official as of 01-Dec-2020	
USP Amiodarone Hydrochloride RS	USP-1027302
USP Amiodarone Related Compound D RS	USP-1027346
USP Amiodarone Related Compound E RS	USP-1027357
USP Amiodarone Related Compound H RS	USP-1027380

MONOGRAPH 2

AMIODARONE HYDROCHLORIDE INJECTION Official as of 01-Jul-2021	
USP Amiodarone Hydrochloride RS	USP-1027302
USP Amiodarone Related Compound D RS	USP-1027346
USP Amiodarone Related Compound E RS	USP-1027357
USP Benzyl Alcohol RS	USP-1061901

MONOGRAPH 3

AMIODARONE HYDROCHLORIDE TABLETS Official as of 01-Feb-2021	
USP Amiodarone Hydrochloride RS	USP-1027302

MONOGRAPH 4

AMIODARONE HYDROCHLORIDE COMPOUNDED ORAL SUSPENSION Official as of 01-Dec-2016	
USP Amiodarone Hydrochloride RS	USP-1027302

PHARMACEUTICAL ANALYTICAL IMPURITY(IES)*	
USP Desiodoamiodarone PAI	USP-1A00720
USP Desethylamiodarone PAI	USP-1A01080
USP Monoiodoamiodarone PAI	USP-1A01090
USP Methoxyamiodarone PAI I *New*	USP-1A00710

** Documents in PF Online are not official and not suitable to demonstrate compliance. They may never become official.*

 # Pharmaceutical Analytical Impurities (PAI products) are released using a process developed by USP's subject matter experts. The release process is based on internal policies, standard operating procedures, and requirements as defined by USP's Quality Management System. USP is an ISO 9001:2015 certified facility. PAI products are different from official USP Reference Standards. PAI products are not required for compendial compliance.

01-Oct-2023. For publications related to **Amiodarone** in *PF* online after this date, please visit the integrated *USP-NF/PF* online.